Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Specialty & Advanced Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:SLXP
- CUSIP: 79543510
- Web: www.salix.com
- 50 Day Moving Avg: $163.00
- 200 Day Moving Avg: $136.00
- 52 Week Range: $86.00 - $173.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 18.78
- P/E Growth: 0
- Net Margins: -2,134.34%
- Return on Equity: -305.24%
- Return on Assets: -25.83%
- Average Volume: 3.35 million shs.
Frequently Asked Questions for Salix Pharmaceuticals (NASDAQ:SLXP)
What is Salix Pharmaceuticals' stock symbol?
Salix Pharmaceuticals trades on the NASDAQ under the ticker symbol "SLXP."
How were Salix Pharmaceuticals' earnings last quarter?
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) released its earnings results on Monday, March, 2nd. The company reported ($2.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $2.32. The firm had revenue of $13 million for the quarter, compared to the consensus estimate of $187.97 million. Salix Pharmaceuticals had a negative return on equity of 305.24% and a negative net margin of 2,134.34%. During the same quarter in the previous year, the firm earned $1.06 EPS. View Salix Pharmaceuticals' Earnings History.
Who are some of Salix Pharmaceuticals' key competitors?
Some companies that are related to Salix Pharmaceuticals include AbbVie (ABBV), ConvaTec Group PLC (CTEC), Mallinckrodt PLC (MNK), Indivior PLC (INDV), Supernus Pharmaceuticals (SUPN), Repligen Corporation (RGEN), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Aimmune Therapeutics (AIMT), Eagle Pharmaceuticals (EGRX), Assembly Biosciences (ASMB), Rockwell Medical (RMTI), NOVAN INC (NOVN), Check-Cap (CHEK), CorMedix (CRMD), Advanced Accelerator Applications S.A. (AAAP), DARA Biosciences (DARA) and Macrocure Ltd (MCUR).
How do I buy Salix Pharmaceuticals stock?
Shares of Salix Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Salix Pharmaceuticals' stock price today?
MarketBeat Community Rating for Salix Pharmaceuticals (NASDAQ SLXP)MarketBeat's community ratings are surveys of what our community members think about Salix Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Salix Pharmaceuticals stock can currently be purchased for approximately $169.00.
Consensus Ratings for Salix Pharmaceuticals (NASDAQ:SLXP) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Salix Pharmaceuticals (NASDAQ:SLXP)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Salix Pharmaceuticals (NASDAQ:SLXP)Earnings History by Quarter for Salix Pharmaceuticals (NASDAQ SLXP)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/2/2015||Q414||($0.29)||($2.61)||$187.97 million||$13.00 million||View||N/A|
|11/6/2014||Q314||$1.56||$1.53||$394.00 million||$354.70 million||View||N/A|
|8/7/2014||Q214||$1.69||$1.59||$397.06 million||$382.00 million||View||Listen|
|5/8/2014||Q114||$0.91||$1.05||$372.91 million||$384.00 million||View||Listen|
|2/27/2014||Q413||$0.93||$1.06||$247.29 million||$257.60 million||View||Listen|
|11/7/2013||Q313||$0.86||$0.89||$239.70 million||$238.20 million||View||N/A|
|8/8/2013||Q2 2013||$0.81||$0.87||$226.34 million||$235.40 million||View||Listen|
|5/9/2013||Q1 2013||$0.67||$0.63||$205.94 million||$202.60 million||View||Listen|
|2/28/2013||Q4 2012||$0.78||$0.81||$199.41 million||$198.17 million||View||N/A|
|11/7/2012||Q312||$0.69||$0.95||$187.23 million||$185.13 million||View||N/A|
Earnings Estimates for Salix Pharmaceuticals (NASDAQ:SLXP)
Current Year EPS Consensus Estimate: $4 EPS
Next Year EPS Consensus Estimate: $9 EPS
Dividend History for Salix Pharmaceuticals (NASDAQ:SLXP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Salix Pharmaceuticals (NASDAQ:SLXP)Insider Trades by Quarter for Salix Pharmaceuticals (NASDAQ:SLXP)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/6/2015||Timothy J Creech||Insider||Sell||4,600||$157.67||$725,282.00|| |
|3/6/2015||William P Forbes||EVP||Sell||20,000||$157.96||$3,159,200.00|| |
|11/12/2014||William P Forbes||EVP||Sell||11,079||$95.05||$1,053,058.95|| |
|6/26/2014||Carolyn J Logan||CEO||Sell||53,057||$123.38||$6,546,172.66|| |
|4/22/2014||Alonzo Thomas D||Director||Sell||11,530||$110.89||$1,278,561.70|| |
|1/10/2014||Alonzo Thomas D||Director||Sell||12,050||$91.83||$1,106,551.50|| |
|1/9/2014||Adam Derbyshire||CFO||Sell||30,001||$91.48||$2,744,491.48|| |
|1/8/2014||William Forbes||EVP||Sell||8,000||$90.06||$720,480.00|| |
|1/7/2014||Rick Scruggs||EVP||Sell||8,463||$88.31||$747,367.53|| |
|1/7/2014||William Keane||Director||Sell||22,500||$88.31||$1,986,975.00|| |
|7/24/2013||William P Forbes||EVP||Sell||12,000||$70.93||$851,160.00|| |
|4/10/2013||William P Forbes||EVP||Sell||8,673||$49.37||$428,186.01|| |
|12/26/2012||Adam C Derbyshire||CFO||Sell||60,000||$41.44||$2,486,400.00|| |
|11/13/2012||Mark A Sirgo||Director||Sell||3,450||$40.53||$139,828.50|| |
Headline Trends for Salix Pharmaceuticals (NASDAQ:SLXP)
Latest Headlines for Salix Pharmaceuticals (NASDAQ:SLXP)
Salix Pharmaceuticals (SLXP) Chart for Saturday, September, 23, 2017